Organic Small Molecule Contrast Agent for Targeted Photoacoustic Imaging of Patient‐Derived Brain Tumors. Issue 21 (1st September 2022)

• Record Type: Journal Article
• Authors: Wu, Min; Xiao, Kai; Liu, Xingang; Yang, Yudan; Song, Gousheng; Xiao, Gelei; Liu, Qing; Yuan, Jian; Liu, Bin
• Is Part Of: Advanced healthcare materials. Volume 11:Issue 21(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-09-01
• Subjects: glioblastoma -- photoacoustic imaging -- patient‐derived cells -- tumor‐targeting; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/adhm.202201640
• Languages: English
• ISSNs: 2192-2640

Abstract

Abstract: Traditional glioblastoma (GBM) cell lines do not maintain the heterogeneity of the original tumor, cell interactions, and therapy response, thus limiting their investigation in GBM theranostics. Herein, a kind of GBM tumor‐targeting nanoparticles (NPs) TCFNP@iRGD are designed and constructed, which are generated by photoacoustic (PA) contrast agent 2‐(3‐cyano‐4, 5, 5‐trimethylfuran‐2(5H)‐ylidene) malononitrile (TCF)‐OH through facile nanoprecipitation and decorated with an active targeting ligand iRGD. Their potential in GBM detection via PA imaging on glioma patient‐derived cells intracranial xenograft models is evaluated for the first time. Excellent tumor‐specific PA mapping performance of GBM is realized by TCFNP@iRGD, demonstrating its promising potential in the clinical diagnosis of GBM. Abstract : Glioblastoma‐targeting photoacoustic imaging is realized in patient‐derived cells intracranial xenograft mice models by organic small contrast agent constructed nanoparticles.